MindWalk (NASDAQ:HYFT – Get Free Report) is one of 109 publicly-traded companies in the “Life Sciences Tools & Services” industry, but how does it weigh in compared to its peers? We will compare MindWalk to related companies based on the strength of its institutional ownership, valuation, earnings, analyst recommendations, dividends, risk and profitability.
Insider and Institutional Ownership
6.7% of MindWalk shares are owned by institutional investors. Comparatively, 53.7% of shares of all “Life Sciences Tools & Services” companies are owned by institutional investors. 6.8% of MindWalk shares are owned by company insiders. Comparatively, 15.0% of shares of all “Life Sciences Tools & Services” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk & Volatility
MindWalk has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, MindWalk’s peers have a beta of 0.94, meaning that their average share price is 6% less volatile than the S&P 500.
Valuation and Earnings
This table compares MindWalk and its peers gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| MindWalk | $11.24 million | -$10.11 million | -4.00 |
| MindWalk Competitors | $2.28 billion | $55.88 billion | -14.01 |
MindWalk’s peers have higher revenue and earnings than MindWalk. MindWalk is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Analyst Ratings
This is a summary of current ratings and recommmendations for MindWalk and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MindWalk | 1 | 1 | 2 | 1 | 2.60 |
| MindWalk Competitors | 948 | 3168 | 5486 | 178 | 2.50 |
MindWalk presently has a consensus price target of $5.00, suggesting a potential upside of 380.77%. As a group, “Life Sciences Tools & Services” companies have a potential downside of 3.81%. Given MindWalk’s stronger consensus rating and higher possible upside, equities research analysts clearly believe MindWalk is more favorable than its peers.
Profitability
This table compares MindWalk and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MindWalk | -105.11% | -133.26% | -77.78% |
| MindWalk Competitors | -540.60% | -166.50% | -13.58% |
Summary
MindWalk peers beat MindWalk on 7 of the 12 factors compared.
About MindWalk
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
Receive News & Ratings for MindWalk Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MindWalk and related companies with MarketBeat.com's FREE daily email newsletter.
